A protein was created where TDP-43 was fused to the SUMO2 protein and these fusion proteins were expressed in cells with or ...

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder that is marked by fasciculation, spasticity and progressive weakness of muscles, and results in difficulty speaking ...

Scientists say an extract of the ancient medicinal plant a shwagandha has shown promise as a potential treatment to slow the symptoms of amyotrophic lateral sclerosis, also known as motor neurone ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with their disorder, a new clinical trial suggests. The drug, tolebrutinib ...

The first two cases highlight cell-based screens that identified medications potentially useful for amyotrophic lateral sclerosis and progressive multifocal leukoencephalopathy, and clinical ...

It is in late-stage clinical development for the treatment of neurodegenerative diseases such as ALS (amyotrophic lateral sclerosis), progressive MS (multiple sclerosis), and DCM (degenerative ...

It came to light after the NCLT in February approved the appointment of EY employee Shailendra Ajmera as the new resolution professional, replacing Srivastava. Raveendran’s lawyers had opposed the ...

It is in late-stage clinical development for the treatment of neurodegenerative diseases such as ALS (amyotrophic lateral sclerosis), progressive MS (multiple sclerosis), and DCM (degenerative ...

Credit: Getty Images In a phase 3, open-label safety extension study, researchers evaluated the safety of oral edaravone in patients with amyotrophic lateral sclerosis over 96 weeks. Oral ...

Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual. Current disease-modifying therapies for multiple ...

More data are needed on its efficacy and safety in treating relapsing multiple sclerosis. In two phase 3, double-blind, double-dummy, event-driven trials (GEMINI 1 and GEMINI 2), participants with ...

While topline results of HERCULES were first presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting last September, the peer-reviewed paper offers ...